-
Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China
•
China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine’s dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million…
-
CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine drug Ayvakit (avapritinib) in an effort to alleviate the financial burden on patients and enhance drug accessibility. The new prices for the 100mg and 300mg versions of the drug are now set at RMB 17,207…
-
Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs
•
China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed at developing multiple novel antibody-drug conjugates (ADCs). The collaboration combines the expertise of both companies to advance the development of innovative cancer treatments. Financial details of the partnership have not been disclosed. Baikai Bi’s ADC…
-
NHC Report: Performance Assessment of National Class 2 Public Hospitals in 2021
•
The National Health Commission (NHC) has released the “Report on the National Monitoring and Analysis of Performance Assessment of National Class 2 Public Hospitals in 2021”. The report indicates that a total of 5,456 Class 2 public hospitals nationwide participated in the 2021 performance evaluation, marking an inclusion of 2,212…
-
Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation
•
Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan Province recently presented updates on their drug and vaccine development projects to a diplomatic delegation from Cuba. Established in 2021, the bi-national institution has a robust pipeline that encompasses cancer, neurology, and infectious diseases, including…
-
Hebei Leads Sanming Alliance in Launching 8th VBP for 19 Medical Consumables
•
The Hebei medical drug and device centralized procurement center has announced the start of the Hebei-led Sanming procurement alliance’s volume-based procurement (VBP) for 19 medical consumables. This marks the eighth consumables VBP led by the Sanming Alliance. Details of the VBP RoundThe round encompasses a range of medical consumables including…
-
Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments
•
The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig (ponatinib) is on track to obtain priority review status for the treatment of specific leukemia conditions in China. These include chronic myeloid leukemia (CML) that is resistant or intolerant to previous medications, recurrent or refractory…
-
Arctic Vision Partners with Sinopharm Group for Ophthalmic Product Distribution in China
•
China-based ophthalmology specialist Arctic Vision has entered into a strategic partnership with Sinopharm Group Distribution Co., Ltd. The collaboration aims to enhance the importation and national commercial distribution of Arctic Vision’s range of ophthalmic products across China. Expanding Distribution and Logistics ServicesUnder the terms of the agreement, Sinopharm Group Distribution…
